Their differences arise mainly from receptor selectivity and the tissues in which muscarinic activation produces the most useful effect. Although all three can engage muscarinic signaling, methacholine is associated with airway responsiveness, carbachol with ocular effects, and bethanechol with urinary and gastrointestinal smooth-muscle activity. This distinction guides drug selection in pharmacology.
Muscarinic receptor activation couples drug binding to intracellular signaling pathways that alter smooth-muscle tone and glandular secretion. The resulting response depends on the tissue exposed and the agonist involved, so the same broad receptor class can produce airway, ocular, urinary, or gastrointestinal outcomes. This tissue-dependent signaling explains their differing pharmacological uses.
An inhaled methacholine challenge uses induced airway narrowing as a functional readout of bronchial hyperresponsiveness. The purpose is diagnostic rather than to promote a therapeutic airway effect: the observed response helps characterize how strongly the airways react to muscarinic stimulation. This makes methacholine especially relevant when airway reactivity is the question.
Methacholine serves primarily as a diagnostic probe of airway reactivity, whereas carbachol and bethanechol are applied for targeted physiological effects. Carbachol is directed toward miosis and intraocular pressure reduction; bethanechol supports bladder and gastrointestinal motility. The contrast demonstrates diagnostic versus therapeutic use of muscarinic agonism.
Carbachol is relevant when a muscarinic response is needed in the eye. Its use produces miosis, meaning pupillary constriction, and helps reduce intraocular pressure. These effects give the drug a distinct ophthalmic role within this group and illustrate how receptor activation can be directed toward a specific clinical outcome.
Bethanechol is chosen when stimulation of urinary or gastrointestinal smooth muscle is the desired outcome. Its pharmacological role centers on supporting bladder function or intestinal motility, rather than testing airway responsiveness or producing an ocular effect. This tissue-oriented application shows how related agonists can serve different therapeutic purposes.